By Jeff Brown, Editor, The Bleeding Edge

Dear Reader,

There’s no going “back to normal.”

My longtime readers already know this, but COVID-19 has changed our world permanently.

We can easily identify the obvious changes. There are more remote working options. Online grocery and food delivery has been quickly adopted. And going forward, industries are rethinking every major conference and public gathering.

But there are also less obvious changes taking place…

Breakthroughs in one technology sector that were 5–10 years away are now happening on a monthly or weekly basis.

Which technology sector am I referring to? Biotechnology.

We’re at the start of a multiyear bull market in biotech. The pandemic has opened the doors for radically new approaches to vaccines and therapies, many of which were not taken seriously before.

It’s going to help us cure diseases at a pace previously unseen.

And for investors, it presents a once-in-a-generation opportunity to create enormous wealth.

The Rise of Biotech

When we picture biotechnology, I imagine 99% of us think of scientists in white lab coats fiddling with test tubes and peering under microscopes.

But the story is far more interesting. As I like to tell readers, biotech is much more “tech” than “bio” these days.

Today, the biotechnology industry is using big data, machine learning, and artificial intelligence to make breakthroughs that – even just a few years ago – would have seemed impossible.

Consider just one example…

Back in March 2020, early stage biotech firm AbCellera did something that many people thought was impossible.

AbCellera received a blood sample from a patient who had recovered from COVID-19. The company used artificial intelligence (AI) to screen more than five million immune cells in that sample. And it identified about 500 antibodies that helped the patient fight off the virus.

AbCellera used this as a starting point to create an antibody therapy for COVID-19.

Historically, this process would have taken years to accomplish. So how long did it take AbCellera? Just 11 days. Beyond incredible.

And the industry took notice…

Pharmaceutical giant Eli Lilly rushed to partner with AbCellera. The companies worked together on a treatment using these antibodies.

In June of last year, AbCellera sent its COVID-19 antibody therapy to clinical trials. It was the first company to do so.

And by November, the antibody treatment, named bamlanivimab, had received emergency use authorization from the U.S. Food and Drug Administration (FDA). The U.S. government has already agreed to purchase 1.45 million doses.

Think about this for a minute. An early stage biotech took blood samples and identified COVID-19 antibodies. It then developed a therapy and launched clinical trials… and then received emergency use authorization. And it did all this in just eight months. Until just recently, this process would have taken several years.

Make no mistake, this is revolutionary work. And it is saving lives.

In all my years as an analyst, I’ve never seen this type of speed from the biotech industry. And it’s thanks in large part to COVID-19. The virus has lit a fire under this overlooked industry.

But investors are now starting to notice…

Money Is Flooding Into Biotech

Suddenly, the world has woken up to the potential of biotechnology.

Every venture capitalist and private equity house has realized how powerful these technologies are and how quickly biotech can move. We’re going to see an acceleration in biotech investment, early stage companies, and IPOs (initial public offerings) as a result.

In fact, we’re already seeing that.

In just the first two months of this year, 42% of all traditional IPOs have been biotechnology companies. And collectively, these companies have raised over $5 billion for drug development.

The 2020s will be the decade of biotech. This will be the first decade in which biotechnology companies truly harness the power of Moore’s Law and demonstrate exponential growth.

For us as investors, we need to be paying attention.

We can think of it this way…

In early 2017, cryptocurrencies were a mostly unknown, niche asset. But then the cryptocurrency space went on an unprecedented bull run before its painful correction in 2018. Bitcoin alone rose over 2,000% in 2017.

And I believe investors’ awareness and engagement in early stage biotech companies will rival that of the crypto bull market back in those early days.

But unlike cryptocurrencies – many of which were backed by nothing – early stage biotech is supported by very real, world-changing technology. The returns we will see from quality biotech companies will create lasting, generational wealth.

We are at the very beginning of a years-long biotech bull market. Breakthroughs will continue to happen. Diseases – previously thought untreatable – will be cured. And, yes, fortunes will be made.

We are entering a golden age of biotechnology. It’s happening right now.

And I believe I’ve found the perfect way to profit from this explosion in biotechnology.

Most investors are distracted by the “big name” biotech stocks they see on CNBC. But hardly anybody is paying attention to a small, niche sector of the biotech market. Here, triple-digit gains are possible in days or even hours.

Thanks to the federal government, these stocks have a preset “timer” attached to their share prices. And once their timers hit zero, these stocks can skyrocket.

I call these investments “Timed Stocks.” And thanks to two forces, they’re actually accelerating.

More of these stocks are coming onto the market. The gains are larger, and they are happening more frequently.

The investment potential here is unlike anything I’ve seen.

I invite you to learn more about “Timed Stocks” by joining me on Thursday, March 18, at 8 p.m. ET.

On that date, I’m hosting Timed Stocks: Final Countdown, a special investing seminar where I’ll reveal everything I’ve learned about these stocks… and I’ll share details about the No. 1 “Timed Stock” on my list.

Go right here to reserve your spot for free. And then mark March 18 on your calendar.

I look forward to seeing you there.


Jeff Brown
Editor, The Bleeding Edge